ClinicalTrials.gg
CompletedNCT05148299Updated Nov 28, 2025Results posted

A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation

A Phase 2 interventional study of Pegcetacoplan in Transplant-Associated Thrombotic Microangiopathy, sponsored by Swedish Orphan Biovitrum. Completed at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Swedish Orphan Biovitrum · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Thrombotic Microangiopathies with a site in Italy — 3 open to participants now, 3 under way, 1 of them phase 3. Thrombotic Microangiopathies · Italy.

Started
2022
the only one that year
Phase 2
3 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Swedish Orphan Biovitrum

Among the 10 studies in Thrombotic Microangiopathies with a site in Italy, this one is the only one that started in 2022, is one of 3 in phase 2, and was the 7th registered.

Thrombotic Microangiopathies

52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.

Browse Thrombotic Microangiopathies studies →

Open to participants now

3 of the 10 studies in Thrombotic Microangiopathies with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Thrombotic Microangiopathies with a site in Italy, or all of them as a file.
02

Study summary

The purpose of the study was to assess pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of pegcetacoplan in patients with TA-TMA after HSCT.

Read the detailed description

This was a pilot study, and the sample size was based on practical rather than statistical aspects.

A total of 12 patients were to be included and treated in the study. With 12 patients included, it was estimated that 9 patients would complete at least 4 weeks of treatment, which is deemed sufficient to characterize the PK of pegcetacoplan in patients with TA-TMA to an appropriate precision. In addition, 12 patients would provide a 72 % probability to observe a response rate of at least 8 responders of the 12 patients recruited (assuming the true response rate is 70 %).

03

Conditions studied

  • Transplant-Associated Thrombotic Microangiopathy

Keywords

  • TA-TMA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥ 18 years at the time of form (ICF) signature.
  2. Received HSCT.
  3. Diagnosis of TA-TMA established, as per laboratory markers indicating TMA.
  4. Have a diagnosis of TA-TMA that persists despite initial management of any triggering condition.
  5. Have random urine protein/creatinine ratio (rUPCR) ≥ 1 mg/mg.
  6. Women of , defined as any women who have experienced menarche and who are NOT permanently sterile or , must have a negative serum pregnancy test at screening and agree to use protocol-defined methods of for the duration of the study and 8 weeks after their last medicinal product (IMP) dose.

    Note: Postmenopausal is defined as having had 12 consecutive months with no menses without an alternative medical cause.

  7. Men must agree to the following for the duration of the study and 8 weeks after their last dose of IMP:

    1. Avoid fathering a child.
    2. Use protocol-defined methods of contraception.
    3. Refrain from donating sperm.
  8. Patient and/or legally authorized representative must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Positive direct Coombs test.
  2. Known familial or acquired ADAMTS13 deficiency.
  3. Known Shiga toxin-related hemolytic uremic syndrome.
  4. Known bone marrow or graft failure.
  5. Diagnosis of disseminated intravascular coagulation.
  6. Diagnosis of veno-occlusive disease (VOD).
  7. Active GI bleeding (hematemesis or hematochezia) at baseline.
  8. Body weight \< 30 kg and > 100 kg.
  9. Uncontrolled systemic bacterial or fungal infection, presence or suspicion of sepsis.
  10. Previously or currently treated with a complement inhibitor (approved or ).
  11. Pregnancy or breastfeeding.
  12. Positive antibody at screening or documented in pre- medical record.
  13. virus detectable by polymerase chain reaction at screening or documented in pre-HSCT medical record.
  14. Chronic inactive virus with viral loads > 1000 IU/mL (> 5000 copies/mL) at screening or documented in pre-HSCT medical record. Eligible patients who are chronic active carriers (≤ 1000 IU/mL) must receive prophylactic antiviral treatment (e.g., entecavir, tenofovir, lamivudine) according to local country guidelines.
  15. Known or suspected hereditary fructose intolerance.
  16. to pegcetacoplan or any of its .
  17. Inability to cooperate with study procedures or any condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or confound the outcome of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Pegcetacoplan

    sterile solution in stoppered glass vial given as infusion, for a total treatment duration of 12 to 16 weeks.

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau)

    Area under the concentration-time curve limited to the end of the dosing interval. The samples included in the calculation of AUC0-tau were collected at the following times: on dosing Days 1, 3 and 5, PK samples were taken up to 30 minutes pre-dose and at 15 minutes (± 5 min), 30 minutes (± 5 min), 1 hour (± 10 min), 4 hours (± 10 min), 8 hours (± 30 min), and 24 hours (± 30 min) post-dose as well as on Day 8 pre-dose.

    Time frame: Week 1

  2. Pegcetacoplan PK Parameter Maximal Serum Concentration (Cmax)

    Maximum observed serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.

    Time frame: Week 1

  3. Pegcetacoplan PK Parameter Time to Cmax (Tmax)

    Time of maximum measured serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.

    Time frame: Week 1

  4. Pegcetacoplan PK Parameter Observed Serum Concentration Pre-dose (Ctrough)

    Observed serum concentration pre-dose. From Day 8 (Week 1) and onwards, PK samples were taken pre-dose at each visit.

    Time frame: Week 1 up to Week 14

Secondary outcomes

  1. Absolute Levels and Change From Baseline in sC5b-9

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation sC5b-9

    Time frame: Week 24

  2. Absolute Levels and Change From Baseline in C3a

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3a

    Time frame: Week 24

  3. Absolute Levels and Change From Baseline in C3

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3

    Time frame: Week 24

  4. Absolute Levels and Change From Baseline in Bb

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation Bb

    Time frame: Week 24

  5. Absolute Levels and Change From Baseline in C4a

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation C4a

    Time frame: Week 24

  6. Absolute Levels and Change From Baseline in Classical Pathway (CH50)

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation CH50

    Time frame: Week 24

  7. Absolute Levels and Change From Baseline in Alternative Pathway (AH50)

    Absolute levels and change from baseline to Week 24 in biomarker of complement activation AH50

    Time frame: Week 24

  8. Number of Participants Reaching Clinical Response at Week 24

    A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms

    Time frame: Week 24

  9. Number of Participants Reaching TMA Response at Week 24

    A participant will be declared as reaching TMA response upon improvement in laboratory markers of TMA

    Time frame: Week 24

  10. Overall Survival at Day 100

    Survival

    Time frame: Day 100 from diagnosis

  11. Overall Survival at Week 24

    Survival

    Time frame: Week 24 from treatment start

  12. Time to Clinical Response

    Both clinical response sustained at week 24 and clinical response at any time during the study will be assessed.

    Time frame: From treatment start to first documentation of attainment of a clinical response, up to 24 weeks

  13. Time to TMA Response

    Both TMA response sustained at week 24 and TMA response at any time during the study will be assessed.

    Time frame: From treatment start to first documentation of attainment of a TMA response, up to 24 weeks

  14. Duration of Clinical Response

    Duration of clinical response sustained at week 24

    Time frame: From the first observed clinical response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks

  15. Duration of TMA Response

    Duration of TMA response sustained at week 24

    Time frame: From the first observed TMA response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks

  16. TA-TMA Relapse at Week 24

    A participant will be declared as relapsing upon appearance of laboratory markers of TMA

    Time frame: Week 24

  17. Number of Participants Reaching Clinical Response at Week 12

    Number of participants reaching clinical response at week 12

    Time frame: Week 12

  18. Number of Participants Reaching TMA Response at Week 12

    Number of participants reaching TMA response at week 12

    Time frame: Week 12

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Occurrence and severity of treatment-emergent adverse events.

    Time frame: From treatment start to end of study, up to 6 months (8 weeks since last dose of IMP)

  2. Change From Baseline in Platelets

    Change from baseline to Week 24 in platelets

    Time frame: Week 24

  3. Change From Baseline in Hemoglobin

    Change from baseline to Week 24 in hemoglobin

    Time frame: Week 24

  4. Change From Baseline in Lactate Dehydrogenase (LDH)

    Change from baseline to Week 24 in LDH

    Time frame: Week 24

  5. Change From Baseline in Haptoglobin

    Change from baseline to Week 24 in haptoglobin

    Time frame: Week 24

  6. Change From Baseline in Indirect Bilirubin

    Change from baseline to Week 24 in indirect bilirubin

    Time frame: Week 24

  7. Change From Baseline in Serum Creatinine

    Change from baseline to Week 24 in serum creatinine

    Time frame: Week 24

  8. Change From Baseline in Urine Protein/Creatinine Ratio

    Change from baseline to Week 24 in urine protein/creatinine ratio

    Time frame: Week 24

  9. Change From Baseline in Systolic Blood Pressure

    Change from baseline to Week 24 in systolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

    Time frame: Week 24

  10. Change From Baseline in Diastolic Blood Pressure

    Change from baseline to Week 24 in diastolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

    Time frame: Week 24

  11. Change From Baseline in Respiratory Rate

    Change from baseline to Week 24 in respiratory rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

    Time frame: Week 24

  12. Change From Baseline in Heart Rate

    Change from baseline to Week 24 in heart rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

    Time frame: Week 24

  13. Change From Baseline in Temperature

    Change from baseline to Week 24 in temperature. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

    Time frame: Week 24

  14. Number of Participants With Clinically Significant Changes in Abnormal Electrocardiogram Findings

    Occurrence of clinically significant abnormal electrocardiogram findings.

    Time frame: Week 24

  15. Number of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods

    Presence of antibodies to pegcetacoplan throughout treatment and follow-up periods.

    Time frame: from treatment start to the end of the study, up to 6 months.

  16. Number of Participants With Antibodies to Polyethylene Glycol (PEG) Throughout Treatment and Follow-up Periods

    Presence of antibodies to PEG throughout treatment and follow-up periods. Baseline represents the situation at treatment start.

    Time frame: from treatment start to the end of the study, up to 6 months.

  17. Number of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods

    Presence of treatment-emergent anti-PEG antibodies throughout treatment and follow-up periods. Conservatively, the anti-PEG antibodies detected in a patient with a missing baseline sample have been considered as treatment-emergent.

    Time frame: from treatment start to the end of the study, up to 6 months.

07

Results

Posted Nov 28, 2025
Limitations and caveats
The small sample size limits the generalizability of the findings.

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePegcetacoplan
Started12
Completed9
Not completed3
Withdrew: Adverse event1
Withdrew: Physician decision1
Withdrew: Death1
Follow-up Period
Participant flow — Follow-up Period
MilestonePegcetacoplan
Started9
Completed6
Not completed3
Withdrew: Death3

Outcome measures

PrimaryPegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau)

Area under the concentration-time curve limited to the end of the dosing interval. The samples included in the calculation of AUC0-tau were collected at the following times: on dosing Days 1, 3 and 5, PK samples were taken up to 30 minutes pre-dose and at 15 minutes (± 5 min), 30 minutes (± 5 min), 1 hour (± 10 min), 4 hours (± 10 min), 8 hours (± 30 min), and 24 hours (± 30 min) post-dose as well as on Day 8 pre-dose.

Time frame:
Week 1
Reported as:
Mean · µg*h/mL
Pegcetacoplan Pharmacokinetic (PK) Parameter Area Under the Curve Limited to the End of Dosing Interval (AUC0-tau)
µg*h/mLPegcetacoplan
Day 1-Day 314934.65 ± 4448.067
Day 3-Day 520089.79 ± 5162.653
Day 5-Day 836208.37 ± 10685.626
PrimaryPegcetacoplan PK Parameter Maximal Serum Concentration (Cmax)

Maximum observed serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.

Time frame:
Week 1
Reported as:
Mean · µg/mL
Pegcetacoplan PK Parameter Maximal Serum Concentration (Cmax)
µg/mLPegcetacoplan
Day 1508.1 ± 134.86
Day 3579.6 ± 142.11
Day 5705.2 ± 203.04
PrimaryPegcetacoplan PK Parameter Time to Cmax (Tmax)

Time of maximum measured serum concentration. Determined using the samples collected post-dose on dosing Days 1, 3 and 5.

Time frame:
Week 1
Reported as:
Median · Hour
Pegcetacoplan PK Parameter Time to Cmax (Tmax)
HourPegcetacoplan
Day 11.0 (0.3 to 48.0)
Day 31.02 (0.3 to 8.5)
Day 51.05 (0.5 to 24.0)
PrimaryPegcetacoplan PK Parameter Observed Serum Concentration Pre-dose (Ctrough)

Observed serum concentration pre-dose. From Day 8 (Week 1) and onwards, PK samples were taken pre-dose at each visit.

Time frame:
Week 1 up to Week 14
Reported as:
Geometric mean · µg/mL
Pegcetacoplan PK Parameter Observed Serum Concentration Pre-dose (Ctrough)
µg/mLPegcetacoplan
Week 1365.22 (308.37 to 432.55)
Week 2449.86 (344.63 to 587.23)
Week 3585.71 (456.62 to 751.30)
Week 4665.32 (501.51 to 882.64)
Week 6750.82 (602.41 to 935.80)
Week 8826.94 (655.21 to 1043.69)
Week 10761.76 (569.21 to 1019.44)
Week 12466.29 (112.54 to 1931.99)
Week 14893.49 (769.46 to 1037.50)
SecondaryAbsolute Levels and Change From Baseline in sC5b-9

Absolute levels and change from baseline to Week 24 in biomarker of complement activation sC5b-9

Time frame:
Week 24
Reported as:
Mean · µg/L
Absolute Levels and Change From Baseline in sC5b-9
µg/LPegcetacoplan
Baseline Absolute Level309.2 ± 200.72
Week 1 Absolute Level175.3 ± 81.26
Week 1 Change from Baseline-133.6 ± 176.13
Week 2 Absolute Level152.0 ± 73.95
Week 2 Change from Baseline-163.0 ± 157.36
Week 3 Absolute Level129.8 ± 43.38
Week 3 Change from Baseline-185.2 ± 194.18
Week 4 Absolute Level161.6 ± 78.37
Week 4 Change from Baseline-142.1 ± 160.54
Week 6 Absolute Level111.7 ± 37.98
Week 6 Change from Baseline-204.0 ± 217.36
Week 8 Absolute Level148.0 ± 45.69
Week 8 Change from Baseline-168.3 ± 226.01
Week 10 Absolute Level131.4 ± 70.60
Week 10 Change from Baseline-184.3 ± 179.44
Week 12 Absolute Level141.2 ± 77.97
Week 12 Change from Baseline-214.0 ± 224.06
Week 14 Absolute Level156.8 ± 65.64
Week 14 Change from Baseline-211.8 ± 211.05
Week 16 Absolute Level158.0 ± 54.21
Week 16 Change from Baseline-210.6 ± 240.97
Week 20 Absolute Level190.0 ± 76.28
Week 20 Change from Baseline-171.6 ± 232.00
Week 24 Absolute Level256.0 ± 122.45
Week 24 Change from Baseline-167.8 ± 162.09
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events

Occurrence and severity of treatment-emergent adverse events.

Time frame:
From treatment start to end of study, up to 6 months (8 weeks since last dose of IMP)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPegcetacoplan
Number of Participants With Treatment-emergent Adverse Events8
Other pre-specifiedChange From Baseline in Platelets

Change from baseline to Week 24 in platelets

Time frame:
Week 24
Reported as:
Mean · 10^9 platelets/L
Change From Baseline in Platelets
10^9 platelets/LPegcetacoplan
Week 112.4 ± 24.22
Week 22.8 ± 12.50
Week 35.1 ± 11.20
Week 418.1 ± 28.61
Week 614.8 ± 21.66
Week 819.6 ± 16.20
Week 1017.6 ± 23.01
Week 1213.4 ± 11.40
Week 1412.3 ± 13.72
Week 1610.6 ± 13.79
Week 2014.9 ± 32.23
Week 2422.6 ± 19.88
Other pre-specifiedChange From Baseline in Hemoglobin

Change from baseline to Week 24 in hemoglobin

Time frame:
Week 24
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin
g/LPegcetacoplan
Week 1-3.8 ± 14.30
Week 28.1 ± 12.48
Week 33.6 ± 14.89
Week 48.0 ± 21.85
Week 62.0 ± 13.20
Week 89.4 ± 15.14
Week 1013.0 ± 15.08
Week 1210.6 ± 16.99
Week 145.7 ± 19.77
Week 167.2 ± 17.64
Week 2013.4 ± 11.04
Week 2414.0 ± 11.02
Other pre-specifiedChange From Baseline in Lactate Dehydrogenase (LDH)

Change from baseline to Week 24 in LDH

Time frame:
Week 24
Reported as:
Mean · U/L
Change From Baseline in Lactate Dehydrogenase (LDH)
U/LPegcetacoplan
Week 1-273.9 ± 310.05
Week 2-315.9 ± 328.13
Week 3-348.2 ± 346.46
Week 4-365.1 ± 363.98
Week 6-408.0 ± 408.28
Week 8-406.0 ± 427.49
Week 10-428.8 ± 425.67
Week 12-480.9 ± 405.14
Week 14-336.3 ± 406.86
Week 16-355.0 ± 396.77
Week 20-242.1 ± 194.73
Week 24-198.0 ± 235.45
SecondaryAbsolute Levels and Change From Baseline in C3a

Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3a

Time frame:
Week 24
Reported as:
Mean · µg/L
Absolute Levels and Change From Baseline in C3a
µg/LPegcetacoplan
Baseline Absolute Level156.9 ± 113.09
Week 1 Absolute Level67.6 ± 70.18
Week 1 Change from Baseline-93.4 ± 120.73
Week 2 Absolute Level126.1 ± 143.32
Week 2 Change from Baseline-27.7 ± 201.41
Week 3 Absolute Level69.3 ± 75.08
Week 3 Change from Baseline-84.4 ± 148.81
Week 4 Absolute Level153.6 ± 184.80
Week 4 Change from Baseline-11.9 ± 209.85
Week 6 Absolute Level54.3 ± 31.97
Week 6 Change from Baseline-74.7 ± 61.34
Week 8 Absolute Level73.0 ± 51.40
Week 8 Change from Baseline-57.5 ± 43.88
Week 10 Absolute Level82.7 ± 51.19
Week 10 Change from Baseline-46.3 ± 44.74
Week 12 Absolute Level218.4 ± 211.57
Week 12 Change from Baseline77.8 ± 207.74
Week 14 Absolute Level141.0 ± 173.84
Week 14 Change from Baseline-3.2 ± 198.30
Week 16 Absolute Level150.8 ± 169.23
Week 16 Change from Baseline6.6 ± 195.38
Week 20 Absolute Level189.8 ± 148.22
Week 20 Change from Baseline75.6 ± 157.49
Week 24 Absolute Level102.4 ± 75.03
Week 24 Change from Baseline-11.5 ± 91.55
SecondaryAbsolute Levels and Change From Baseline in C3

Absolute levels and change from baseline to Week 24 in biomarker of complement activation C3

Time frame:
Week 24
Reported as:
Mean · g/L
Absolute Levels and Change From Baseline in C3
g/LPegcetacoplan
Baseline Absolute Level1.095 ± 0.2893
Week 1 Absolute Level2.500 ± 0.6503
Week 1 Change from Baseline1.313 ± 0.5038
Week 2 Absolute Level3.095 ± 0.8883
Week 2 Change from Baseline1.929 ± 0.7034
Week 3 Absolute Level2.883 ± 0.9188
Week 3 Change from Baseline1.824 ± 0.7698
Week 4 Absolute Level3.716 ± 0.9693
Week 4 Change from Baseline2.399 ± 0.7395
Week 6 Absolute Level3.934 ± 0.8033
Week 6 Change from Baseline2.777 ± 0.7718
Week 8 Absolute Level4.238 ± 0.4511
Week 8 Change from Baseline3.040 ± 0.3240
Week 10 Absolute Level3.920 ± 1.0524
Week 10 Change from Baseline2.814 ± 0.9156
Week 12 Absolute Level4.061 ± 1.7835
Week 12 Change from Baseline2.893 ± 1.7103
Week 14 Absolute Level4.156 ± 1.1392
Week 14 Change from Baseline2.957 ± 0.9774
Week 16 Absolute Level4.320 ± 1.2352
Week 16 Change from Baseline3.177 ± 1.2536
Week 20 Absolute Level2.052 ± 0.9091
Week 20 Change from Baseline0.858 ± 0.9097
Week 24 Absolute Level1.338 ± 0.5070
Week 24 Change from Baseline0.047 ± 0.3580
SecondaryAbsolute Levels and Change From Baseline in Bb

Absolute levels and change from baseline to Week 24 in biomarker of complement activation Bb

Time frame:
Week 24
Reported as:
Mean · mg/L
Absolute Levels and Change From Baseline in Bb
mg/LPegcetacoplan
Baseline Absolute Level2.098 ± 1.5087
Week 1 Absolute Level0.769 ± 0.4819
Week 1 Change from Baseline-1.404 ± 1.2250
Week 2 Absolute Level0.726 ± 0.2783
Week 2 Change from Baseline-1.354 ± 1.4238
Week 3 Absolute Level0.611 ± 0.1335
Week 3 Change from Baseline-1.469 ± 1.6091
Week 4 Absolute Level0.749 ± 0.1857
Week 4 Change from Baseline-1.458 ± 1.6256
Week 6 Absolute Level0.617 ± 0.1485
Week 6 Change from Baseline-1.720 ± 1.7170
Week 8 Absolute Level0.632 ± 0.1308
Week 8 Change from Baseline-1.858 ± 1.8627
Week 10 Absolute Level0.704 ± 0.2522
Week 10 Change from Baseline-1.633 ± 1.6250
Week 12 Absolute Level0.746 ± 0.3340
Week 12 Change from Baseline-2.034 ± 1.6738
Week 14 Absolute Level0.528 ± 0.1555
Week 14 Change from Baseline-1.968 ± 1.9232
Week 16 Absolute Level0.672 ± 0.3385
Week 16 Change from Baseline-1.824 ± 1.9516
Week 20 Absolute Level0.600 ± 0.2507
Week 20 Change from Baseline-0.966 ± 1.1270
Week 24 Absolute Level0.746 ± 0.0631
Week 24 Change from Baseline-1.015 ± 1.1970
SecondaryAbsolute Levels and Change From Baseline in C4a

Absolute levels and change from baseline to Week 24 in biomarker of complement activation C4a

Time frame:
Week 24
Reported as:
Mean · ug/L
Absolute Levels and Change From Baseline in C4a
ug/LPegcetacoplan
Baseline Absolute Level3422.9 ± 2792.23
Week 1 Absolute Level1724.6 ± 1219.46
Week 1 Change from Baseline-1470.8 ± 3194.16
Week 2 Absolute Level4644.1 ± 4426.51
Week 2 Change from Baseline1263.3 ± 3370.74
Week 3 Absolute Level4118.0 ± 4192.86
Week 3 Change from Baseline737.2 ± 3316.77
Week 4 Absolute Level4504.8 ± 3690.83
Week 4 Change from Baseline811.8 ± 1763.02
Week 6 Absolute Level3582.6 ± 3559.59
Week 6 Change from Baseline-438.7 ± 5670.06
Week 8 Absolute Level2792.5 ± 3573.91
Week 8 Change from Baseline-987.2 ± 1295.21
Week 10 Absolute Level2234.7 ± 2012.23
Week 10 Change from Baseline-1786.6 ± 2007.28
Week 12 Absolute Level5171.6 ± 4735.92
Week 12 Change from Baseline852.0 ± 4487.81
Week 14 Absolute Level2618.2 ± 4142.08
Week 14 Change from Baseline-2269.8 ± 4901.62
Week 16 Absolute Level1731.8 ± 1285.26
Week 16 Change from Baseline-3156.2 ± 3051.14
Week 20 Absolute Level4007.8 ± 3648.52
Week 20 Change from Baseline-664.6 ± 3821.60
Week 24 Absolute Level4329.2 ± 2520.61
Week 24 Change from Baseline-403.5 ± 2475.95
SecondaryAbsolute Levels and Change From Baseline in Classical Pathway (CH50)

Absolute levels and change from baseline to Week 24 in biomarker of complement activation CH50

Time frame:
Week 24
Reported as:
Mean · U/mL
Absolute Levels and Change From Baseline in Classical Pathway (CH50)
U/mLPegcetacoplan
Baseline Absolute Level92.2 ± 17.94
Week 1 Absolute Level99.6 ± 29.99
Week 1 Change from Baseline7.2 ± 28.48
Week 2 Absolute Level116.9 ± 18.98
Week 2 Change from Baseline21.9 ± 25.30
Week 3 Absolute Level114.9 ± 27.09
Week 3 Change from Baseline21.0 ± 35.76
Week 4 Absolute Level107.7 ± 21.72
Week 4 Change from Baseline12.1 ± 13.64
Week 6 Absolute Level114.9 ± 19.36
Week 6 Change from Baseline25.1 ± 30.72
Week 8 Absolute Level123.4 ± 32.40
Week 8 Change from Baseline31.8 ± 35.78
Week 10 Absolute Level121.1 ± 34.98
Week 10 Change from Baseline25.5 ± 29.59
Week 12 Absolute Level103.0 ± 45.15
Week 12 Change from Baseline12.7 ± 42.57
Week 14 Absolute Level127.4 ± 34.81
Week 14 Change from Baseline35.2 ± 44.74
Week 16 Absolute Level129.9 ± 30.42
Week 16 Change from Baseline32.7 ± 37.69
Week 20 Absolute Level119.6 ± 43.93
Week 20 Change from Baseline26.3 ± 46.44
Week 24 Absolute Level106.8 ± 51.10
Week 24 Change from Baseline17.0 ± 73.63
SecondaryAbsolute Levels and Change From Baseline in Alternative Pathway (AH50)

Absolute levels and change from baseline to Week 24 in biomarker of complement activation AH50

Time frame:
Week 24
Reported as:
Mean · U/mL
Absolute Levels and Change From Baseline in Alternative Pathway (AH50)
U/mLPegcetacoplan
Baseline Absolute Level125.8 ± 44.75
Week 1 Absolute Level75.0 ± 57.85
Week 1 Change from Baseline-55.3 ± 49.73
Week 2 Absolute Level65.9 ± 49.10
Week 2 Change from Baseline-47.7 ± 49.15
Week 3 Absolute Level34.7 ± 34.38
Week 3 Change from Baseline-80.7 ± 38.62
Week 4 Absolute Level35.4 ± 38.46
Week 4 Change from Baseline-79.9 ± 36.02
Week 6 Absolute Level24.0 ± 40.27
Week 6 Change from Baseline-85.3 ± 38.05
Week 8 Absolute Level23.6 ± 43.47
Week 8 Change from Baseline-85.8 ± 43.81
Week 10 Absolute Level36.9 ± 54.84
Week 10 Change from Baseline-71.3 ± 55.56
Week 12 Absolute Level60.6 ± 69.54
Week 12 Change from Baseline-49.5 ± 43.34
Week 14 Absolute Level20.0 ± 41.81
Week 14 Change from Baseline-96.5 ± 45.17
Week 16 Absolute Level35.9 ± 51.88
Week 16 Change from Baseline-84.8 ± 37.55
Week 20 Absolute Level118.1 ± 23.74
Week 20 Change from Baseline7.8 ± 55.02
Week 24 Absolute Level129.4 ± 19.03
Week 24 Change from Baseline11.5 ± 63.67
SecondaryNumber of Participants Reaching Clinical Response at Week 24

A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Reaching Clinical Response at Week 24
ParticipantsPegcetacoplan
Number of Participants Reaching Clinical Response at Week 240
SecondaryNumber of Participants Reaching TMA Response at Week 24

A participant will be declared as reaching TMA response upon improvement in laboratory markers of TMA

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Reaching TMA Response at Week 24
ParticipantsPegcetacoplan
Number of Participants Reaching TMA Response at Week 242
SecondaryOverall Survival at Day 100

Survival

Time frame:
Day 100 from diagnosis
Reported as:
Count of participants · Participants
Overall Survival at Day 100
ParticipantsPegcetacoplan
Overall Survival at Day 1008
SecondaryOverall Survival at Week 24

Survival

Time frame:
Week 24 from treatment start
Reported as:
Count of participants · Participants
Overall Survival at Week 24
ParticipantsPegcetacoplan
Overall Survival at Week 246
SecondaryTime to Clinical Response

Both clinical response sustained at week 24 and clinical response at any time during the study will be assessed.

Time frame:
From treatment start to first documentation of attainment of a clinical response, up to 24 weeks
Reported as:
Median · Weeks
Time to Clinical Response
WeeksPegcetacoplan
Time to Clinical ResponseNA (2.00 to NA)
SecondaryTime to TMA Response

Both TMA response sustained at week 24 and TMA response at any time during the study will be assessed.

Time frame:
From treatment start to first documentation of attainment of a TMA response, up to 24 weeks
Reported as:
Median · Weeks
Time to TMA Response
WeeksPegcetacoplan
Time to TMA Response24.0 (6.14 to NA)
SecondaryDuration of Clinical Response

Duration of clinical response sustained at week 24

Time frame:
From the first observed clinical response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks
Reported as:
Median · Weeks
Duration of Clinical Response
WeeksPegcetacoplan
Duration of Clinical Response1.6 (1.3 to 2.0)
SecondaryDuration of TMA Response

Duration of TMA response sustained at week 24

Time frame:
From the first observed TMA response until the response criteria is no longer fulfilled or until end of study, up to 24 weeks
Reported as:
Median · Weeks
Duration of TMA Response
WeeksPegcetacoplan
Duration of TMA Response4.0 (2.0 to 6.1)
SecondaryTA-TMA Relapse at Week 24

A participant will be declared as relapsing upon appearance of laboratory markers of TMA

Time frame:
Week 24
Reported as:
Count of participants · Participants
TA-TMA Relapse at Week 24
ParticipantsPegcetacoplan
TA-TMA Relapse at Week 240
SecondaryNumber of Participants Reaching Clinical Response at Week 12

Number of participants reaching clinical response at week 12

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Reaching Clinical Response at Week 12
ParticipantsPegcetacoplan
Number of Participants Reaching Clinical Response at Week 121
SecondaryNumber of Participants Reaching TMA Response at Week 12

Number of participants reaching TMA response at week 12

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Reaching TMA Response at Week 12
ParticipantsPegcetacoplan
Number of Participants Reaching TMA Response at Week 122
Other pre-specifiedChange From Baseline in Haptoglobin

Change from baseline to Week 24 in haptoglobin

Time frame:
Week 24
Reported as:
Mean · g/L
Change From Baseline in Haptoglobin
g/LPegcetacoplan
Week 10.070 ± 0.2280
Week 20.244 ± 0.4553
Week 30.179 ± 0.5054
Week 40.260 ± 0.5674
Week 60.590 ± 0.6451
Week 80.388 ± 0.4496
Week 100.578 ± 0.5832
Week 120.625 ± 0.6279
Week 140.620 ± 0.7013
Week 160.657 ± 0.6629
Week 200.686 ± 0.7459
Week 240.778 ± 0.5427
Other pre-specifiedChange From Baseline in Indirect Bilirubin

Change from baseline to Week 24 in indirect bilirubin

Time frame:
Week 24
Reported as:
Mean · umol/L
Change From Baseline in Indirect Bilirubin
umol/LPegcetacoplan
Week 1-7.80 ± 14.213
Week 2-9.73 ± 12.344
Week 3-9.71 ± 14.683
Week 4-9.87 ± 15.239
Week 6-8.95 ± 18.202
Week 8-11.98 ± 21.787
Week 10-10.24 ± 18.390
Week 12-10.71 ± 23.203
Week 14-14.03 ± 26.164
Week 16-13.70 ± 27.536
Week 20-3.23 ± 9.330
Week 24-3.65 ± 7.769
Other pre-specifiedChange From Baseline in Serum Creatinine

Change from baseline to Week 24 in serum creatinine

Time frame:
Week 24
Reported as:
Mean · umol/L
Change From Baseline in Serum Creatinine
umol/LPegcetacoplan
Week 112.14 ± 42.106
Week 2-3.84 ± 64.131
Week 3-14.93 ± 66.231
Week 4-28.32 ± 101.178
Week 6-8.80 ± 78.912
Week 8-6.24 ± 72.867
Week 10-7.99 ± 86.096
Week 12-22.04 ± 64.786
Week 1416.13 ± 43.379
Week 1614.13 ± 39.711
Week 2017.77 ± 24.444
Week 2411.30 ± 17.470
Other pre-specifiedChange From Baseline in Urine Protein/Creatinine Ratio

Change from baseline to Week 24 in urine protein/creatinine ratio

Time frame:
Week 24
Reported as:
Mean · mg/mg cr
Change From Baseline in Urine Protein/Creatinine Ratio
mg/mg crPegcetacoplan
Week 1-1.0821 ± 1.90348
Week 20.2738 ± 3.95639
Week 3-0.8321 ± 1.74384
Week 45.4769 ± 18.92243
Week 6-0.7370 ± 1.25579
Week 8-0.5807 ± 1.27999
Week 10-0.7423 ± 1.32039
Week 12-0.9154 ± 1.52232
Week 14-0.9039 ± 1.54815
Week 16-0.8121 ± 1.78436
Week 20-0.3050 ± 1.15634
Week 24-0.7543 ± 0.56060
Other pre-specifiedChange From Baseline in Systolic Blood Pressure

Change from baseline to Week 24 in systolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

Time frame:
Week 24
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure
mmHgPegcetacoplan
Week 1 Pre-dose-5.0 ± 20.30
Week 1 Post-dose-8.7 ± 14.24
Week 2 Pre-dose3.9 ± 17.48
Week 2 Post-dose-0.4 ± 17.32
Week 3 Pre-dose1.3 ± 22.46
Week 3 Post-dose-13.2 ± 9.97
Week 4 Pre-dose-7.6 ± 15.18
Week 4 Post-dose-12.0 ± 14.31
Week 6 Pre-dose-10.7 ± 16.71
Week 6 Post-dose-24.3 ± 8.66
Week 8 Pre-dose-9.1 ± 19.46
Week 8 Post-dose-13.2 ± 10.48
Week 10 Pre-dose-7.7 ± 16.02
Week 10 Post-dose-8.4 ± 17.07
Week 12 Pre-dose-10.6 ± 21.47
Week 12 Post-dose-15.0 ± 10.15
Week 14 Pre-dose-4.0 ± 17.67
Week 14 Post-dose-11.3 ± 21.96
Week 16-13.3 ± 12.09
Week 20-13.7 ± 12.32
Week 24-8.3 ± 12.24
Other pre-specifiedChange From Baseline in Diastolic Blood Pressure

Change from baseline to Week 24 in diastolic blood pressure. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

Time frame:
Week 24
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure
mmHgPegcetacoplan
Week 1 Pre-dose-4.5 ± 9.21
Week 1 Post-dose-5.1 ± 7.41
Week 2 Pre-dose-2.2 ± 10.28
Week 2 Post-dose-6.0 ± 11.58
Week 3 Pre-dose-2.1 ± 11.50
Week 3 Post-dose-9.2 ± 3.43
Week 4 Pre-dose-7.6 ± 8.88
Week 4 Post-dose-7.3 ± 6.63
Week 6 Pre-dose-7.0 ± 9.42
Week 6 Post-dose-12.8 ± 7.50
Week 8 Pre-dose-7.9 ± 8.98
Week 8 Post-dose-11.3 ± 9.46
Week 10 Pre-dose-7.1 ± 8.88
Week 10 Post-dose-7.2 ± 13.20
Week 12 Pre-dose-8.6 ± 10.86
Week 12 Post-dose-10.8 ± 8.58
Week 14 Pre-dose-5.1 ± 9.04
Week 14 Post-dose-7.7 ± 16.77
Week 16-8.3 ± 8.77
Week 20-10.6 ± 7.28
Week 24-13.2 ± 9.09
Other pre-specifiedChange From Baseline in Respiratory Rate

Change from baseline to Week 24 in respiratory rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

Time frame:
Week 24
Reported as:
Mean · breaths/min
Change From Baseline in Respiratory Rate
breaths/minPegcetacoplan
Week 1 Pre-dose-0.5 ± 1.69
Week 1 Post-dose-0.1 ± 0.93
Week 2 Pre-dose-0.8 ± 1.69
Week 2 Post-dose-0.3 ± 0.71
Week 3 Pre-dose0.0 ± 1.15
Week 3 Post-dose0.5 ± 0.55
Week 4 Pre-dose1.0 ± 2.45
Week 4 Post-dose1.1 ± 2.04
Week 6 Pre-dose0.4 ± 1.67
Week 6 Post-dose0.5 ± 1.00
Week 8 Pre-dose0.3 ± 0.87
Week 8 Post-dose-0.2 ± 1.47
Week 10 Pre-dose0.0 ± 1.41
Week 10 Post-dose0.0 ± 1.58
Week 12 Pre-dose1.4 ± 2.62
Week 12 Post-dose0.6 ± 0.55
Week 14 Pre-dose0.4 ± 1.27
Week 14 Post-dose0.0 ± 1.73
Week 160.7 ± 1.21
Week 200.3 ± 1.25
Week 240.2 ± 1.47
Other pre-specifiedChange From Baseline in Heart Rate

Change from baseline to Week 24 in heart rate. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

Time frame:
Week 24
Reported as:
Mean · bpm
Change From Baseline in Heart Rate
bpmPegcetacoplan
Week 1 Pre-dose-7.4 ± 9.91
Week 1 Post-dose-7.3 ± 8.60
Week 2 Pre-dose-4.3 ± 9.20
Week 2 Post-dose-3.6 ± 11.93
Week 3 Pre-dose-7.8 ± 8.73
Week 3 Post-dose-5.5 ± 6.06
Week 4 Pre-dose-7.3 ± 7.76
Week 4 Post-dose-8.3 ± 11.28
Week 6 Pre-dose-6.4 ± 3.78
Week 6 Post-dose-8.5 ± 4.51
Week 8 Pre-dose-9.2 ± 6.44
Week 8 Post-dose-9.3 ± 2.25
Week 10 Pre-dose-6.3 ± 6.22
Week 10 Post-dose-5.2 ± 9.96
Week 12 Pre-dose-5.8 ± 8.00
Week 12 Post-dose-11.2 ± 2.68
Week 14 Pre-dose-5.1 ± 12.33
Week 14 Post-dose1.7 ± 7.51
Week 16-12.3 ± 10.03
Week 20-8.6 ± 9.57
Week 24-6.3 ± 9.97
Other pre-specifiedChange From Baseline in Temperature

Change from baseline to Week 24 in temperature. Post-dose is 30 minutes after stop of infusion. The timepoints from Week 16 onward have a single value as no infusions were administered at these study visits.

Time frame:
Week 24
Reported as:
Mean · Celsius
Change From Baseline in Temperature
CelsiusPegcetacoplan
Week 1 Pre-dose0.10 ± 0.671
Week 1 Post-dose-0.19 ± 0.298
Week 2 Pre-dose-0.08 ± 0.311
Week 2 Post-dose-0.13 ± 0.224
Week 3 Pre-dose-0.07 ± 0.157
Week 3 Post-dose-0.05 ± 0.197
Week 4 Pre-dose-0.03 ± 0.173
Week 4 Post-dose0.02 ± 0.075
Week 6 Pre-dose-0.10 ± 0.235
Week 6 Post-dose0.03 ± 0.150
Week 8 Pre-dose-0.09 ± 0.322
Week 8 Post-dose-0.04 ± 0.207
Week 10 Pre-dose0.14 ± 0.485
Week 10 Post-dose0.02 ± 0.277
Week 12 Pre-dose-0.05 ± 0.273
Week 12 Post-dose0.06 ± 0.152
Week 14 Pre-dose-0.13 ± 0.256
Week 14 Post-dose-0.07 ± 0.379
Week 16-0.14 ± 0.299
Week 20-0.31 ± 0.430
Week 24-0.30 ± 0.522
Other pre-specifiedNumber of Participants With Clinically Significant Changes in Abnormal Electrocardiogram Findings

Occurrence of clinically significant abnormal electrocardiogram findings.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Abnormal Electrocardiogram Findings
ParticipantsPegcetacoplan
Baseline — Normal3
Baseline — Abnormal, not clinically significant9
Baseline — Abnormal, clinically significant0
Week 1 — Normal3
Week 1 — Abnormal, not clinically significant8
Week 1 — Abnormal, clinically significant0
Week 2 — Normal4
Week 2 — Abnormal, not clinically significant6
Week 2 — Abnormal, clinically significant0
Week 3 — Normal3
Week 3 — Abnormal, not clinically significant6
Week 3 — Abnormal, clinically significant0
Week 4 — Normal3
Week 4 — Abnormal, not clinically significant7
Week 4 — Abnormal, clinically significant0
Week 6 — Normal4
Week 6 — Abnormal, not clinically significant5
Week 6 — Abnormal, clinically significant0
Week 8 — Normal4
Week 8 — Abnormal, not clinically significant5
Week 8 — Abnormal, clinically significant0
Week 10 — Normal3
Week 10 — Abnormal, not clinically significant6
Week 10 — Abnormal, clinically significant0
Week 12 — Normal3
Week 12 — Abnormal, not clinically significant5
Week 12 — Abnormal, clinically significant0
Week 14 — Normal3
Week 14 — Abnormal, not clinically significant4
Week 14 — Abnormal, clinically significant0
Week 16 — Normal2
Week 16 — Abnormal, not clinically significant4
Week 16 — Abnormal, clinically significant0
Week 20 — Normal2
Week 20 — Abnormal, not clinically significant4
Week 20 — Abnormal, clinically significant0
Week 24 — Normal1
Week 24 — Abnormal, not clinically significant4
Week 24 — Abnormal, clinically significant0
Other pre-specifiedNumber of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods

Presence of antibodies to pegcetacoplan throughout treatment and follow-up periods.

Time frame:
from treatment start to the end of the study, up to 6 months.
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods
ParticipantsPegcetacoplan
Number of Participants With Antibodies to Pegcetacoplan Throughout Treatment and Follow-up Periods0
Other pre-specifiedNumber of Participants With Antibodies to Polyethylene Glycol (PEG) Throughout Treatment and Follow-up Periods

Presence of antibodies to PEG throughout treatment and follow-up periods. Baseline represents the situation at treatment start.

Time frame:
from treatment start to the end of the study, up to 6 months.
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to Polyethylene Glycol (PEG) Throughout Treatment and Follow-up Periods
ParticipantsPegcetacoplan
Baseline — Positive10
Baseline — Negative1
Week 1 — Positive1
Week 1 — Negative0
Week 2 — Positive6
Week 2 — Negative1
Week 4 — Positive4
Week 4 — Negative2
Week 12 — Positive3
Week 12 — Negative2
Week 16 — Positive1
Week 16 — Negative2
Week 20 — Positive2
Week 20 — Negative2
Week 24 — Positive1
Week 24 — Negative1
Other pre-specifiedNumber of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods

Presence of treatment-emergent anti-PEG antibodies throughout treatment and follow-up periods. Conservatively, the anti-PEG antibodies detected in a patient with a missing baseline sample have been considered as treatment-emergent.

Time frame:
from treatment start to the end of the study, up to 6 months.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods
ParticipantsPegcetacoplan
Number of Participants With Treatment-emergent Anti-PEG Antibodies Throughout Treatment and Follow-up Periods2

Adverse events

Collected over From the first dose of IMP and up to 8 weeks after the date of administration of the last dose of IMP, up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan6/12 (50%)8/12 (66.7%)5/12 (41.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPegcetacoplan
Respiratory failureRespiratory, thoracic and mediastinal disorders2/12
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/12
Pleural effusionRespiratory, thoracic and mediastinal disorders1/12
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/12
Generalised tonic-clonic seizureNervous system disorders1/12
Haemorrhagic strokeNervous system disorders1/12
Neuropathy peripheralNervous system disorders1/12
Cardiac failureCardiac disorders1/12
Cardiac failure congestiveCardiac disorders1/12
Bronchopulmonary aspergillosisInfections and infestations1/12
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPegcetacoplan
DiarrheaGastrointestinal disorders3/12
VomitingGastrointestinal disorders2/12
PyrexiaGeneral disorders2/12
Decubitus ulcerSkin and subcutaneous tissue disorders2/12
Abdominal painGastrointestinal disorders1/12
HemoperitoneumGastrointestinal disorders1/12
NauseaGastrointestinal disorders1/12
Oral painGastrointestinal disorders1/12
Pleural effusionRespiratory, thoracic and mediastinal disorders1/12
BronchospasmRespiratory, thoracic and mediastinal disorders1/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pegcetacoplan
<=18 years0
Between 18 and 65 years10
>=65 years2
Age, Continuous
Age, Continuous(Years)Pegcetacoplan
Median50.5 (19 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan
Female6
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegcetacoplan
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegcetacoplan
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Pegcetacoplan
Greece7
United States3
Spain2
Female of childbearing potential
Female of childbearing potential(Participants)Pegcetacoplan
Yes2
No (surgical sterilization)0
No (hysterectomy)0
No (post-menopausal more than 1 year)4
Male method of contraception
Male method of contraception(Participants)Pegcetacoplan
Sterilization0
Condom0
Abstinence6
Other0

39 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • City of Hope
    Duarte, California 91010, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Saint-Louis Hospital
    Paris, Paris 75010, France
  • Archet 1 hospital, Department of Clinical Hematology
    Nice, 06200, France
  • CHU de Saint-Etienne
    Saint-Priest-en-Jarez, 42270, France
  • University General Hospital "Attikon"
    Athens, Chaidari 12462, Greece
  • General Hospital of Athens "Evangelismos"
    Athens, 10676, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou", Hematology Department - BMT Unit
    Thessaloniki, 57010, Greece
  • Hospital San Giuseppe Moscati
    Avellino, 83100, Italy
  • Big Metropolitan Hospital Niguarda Regional Health Authority
    Milan, 20162, Italy
  • ASST Monza - S. Gerardo Hospital
    Monza, 20900, Italy
  • United Hospitals Villa Sofia Cervello
    Palermo, 90146, Italy
  • University Polyclinic Foundation "Agostino Gemelli" - IRCCS
    Roma, 00168, Italy
  • University Hospital Puerta de Hierro Majadahonda
    Madrid, 28222, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Dec 2024, 34 months.

Results were first posted in Nov 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2021
First posted
Dec 8, 2021
StartActual
Feb 1, 2022
Primary completionActual
Dec 8, 2024
CompletionActual
Dec 8, 2024
Results first posted
Nov 28, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05148299
Responsible party
Sponsor
First posted
Dec 8, 2021
Start date
Feb 1, 2022
Primary completion
Dec 8, 2024
Completion
Dec 8, 2024
Results posted
Nov 28, 2025
Last update
Nov 28, 2025

Study contacts

Study physician
study director · Swedish Orphan Biovitrum

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion